On May 16, 2025, Qingdao Baheal Pharma Co., Ltd, a subsidiary of Baheal Pharma under Baheal Medical (301015.SZ), held a relocation ceremony to celebrate its Phase III construction project. Mr. Zhu Xiaowei, Director of Baheal Pharma Group, Vice President of Baheal Medical and Chairman of Baheal Pharma, Mr. Hao Yu, Vice President of Baheal Pharma Group's Campus Operation, Ms. Zheng Aiju, General Manager of Qingdao Baheal Pharma, and other leaders and guests, as well as colleagues of Qingdao Baheal Pharma, were present at the ceremony to witness this important moment together.

On February 22, 2025, the "China Intracranial Metastases Consortium" (CLAIM) held its founding meeting and the first Xuanwu Intracranial Metastases Forum in Beijing. The event brought together nearly 170 experts and scholars from 108 hospitals, spanning oncology, radiotherapy, neurosurgery, pathology, and imaging departments, to discuss multidisciplinary approaches to treating intracranial metastases, intending to enhance patient survival.

February 13, 2025 - Qingdao Baheal Pharma Co., Ltd. (hereinafter referred to as "Baheal Medical," 301015.SZ), a leading pharmaceutical industrialization platform, has announced a new commercial collaboration with Shanghai Roche Pharmaceuticals Ltd. ("Roche Pharmaceuticals China").

The Ministry of Science and Technology recently announced projects under the "14th Five-Year Plan" National Key R&D Program, prioritizing "Diagnostic Equipment and Biomedical Materials." Notably, for the first time, cardiac radiotherapy technology has been included as a focus area. The project "Development of Stereotactic Radiotherapy Technology and Prototype for Cardiac Arrhythmia," led by Huake Pioneer, a medical linear accelerator developer, was successfully selected.

and 3D Disease Modeling Joint Laboratory On December 18, 2024, the "High-Quality Development Forum" was hosted by the Institute of Advanced Clinical Medicine at Peking University (IACM). During the event, Baheal's invested enterprise, CAIUSLY Technology Co., Ltd. (CAIUSLY), signed an agreement with IACM to co-establish the "Organ-on-a-Chip and 3D Disease Modeling Joint Laboratory".